Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Sees Significant Increase in Short Interest

Posted by George Bondi on Jun 11th, 2026

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT – Get Free Report) was the target of a large increase in short interest during the month of May. As of May 29th, there was short interest totaling 246,970 shares, an increase of 252.3% from the May 14th total of 70,108 shares. Approximately 1.8% of the company’s shares are sold short. Based on an average daily trading volume, of 112,419 shares, the days-to-cover ratio is currently 2.2 days.

Institutional Trading of Lixte Biotechnology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LIXT. Axxcess Wealth Management LLC acquired a new stake in Lixte Biotechnology during the 4th quarter valued at approximately $54,000. Geode Capital Management LLC increased its position in Lixte Biotechnology by 25.9% during the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock valued at $205,000 after purchasing an additional 10,722 shares during the period. Renaissance Technologies LLC increased its position in Lixte Biotechnology by 47.0% during the 4th quarter. Renaissance Technologies LLC now owns 107,500 shares of the company’s stock valued at $422,000 after purchasing an additional 34,350 shares during the period. DRW Securities LLC increased its position in Lixte Biotechnology by 11.6% during the 4th quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock valued at $213,000 after purchasing an additional 5,645 shares during the period. Finally, Federation des caisses Desjardins du Quebec increased its position in Lixte Biotechnology by 83.6% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock valued at $367,000 after purchasing an additional 42,530 shares during the period. Institutional investors and hedge funds own 5.10% of the company’s stock.

Lixte Biotechnology Price Performance

NASDAQ LIXT traded up $0.36 during trading hours on Thursday, reaching $7.25. The company’s stock had a trading volume of 442,109 shares, compared to its average volume of 193,486. The firm has a fifty day simple moving average of $4.74 and a 200-day simple moving average of $3.91. The stock has a market cap of $108.90 million, a P/E ratio of -6.42 and a beta of 1.27. Lixte Biotechnology has a 52 week low of $0.64 and a 52 week high of $7.51.

Lixte Biotechnology (NASDAQ:LIXT – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.18) earnings per share for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Lixte Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 26th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Get Our Latest Analysis on Lixte Biotechnology

Lixte Biotechnology Company Profile

(Get Free Report)

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.